News

4D Molecular Therapeutics, Inc.: 4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027 from H2 2027 and 4FRONT-2 initiated ahead of schedulePresented positive 60-week res ...